Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 30, 1994

Primary Completion Date

February 29, 1996

Study Completion Date

February 29, 1996

Conditions
HIV InfectionsCMV Cytomegalovirus Retinitis
Interventions
DRUG

Cidofovir

"Three groups:~1. the deferral group, treatment deferred until retinitis progressed~2. Low-dose cidofovir group, 5 mg/kg of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks.~3. High-dose cidofovir group, 5mg/kg once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks."

All Listed Sponsors
collaborator

Baylor College of Medicine

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

Louisiana State University Health Sciences Center in New Orleans

OTHER

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

New Jersey Medical School

OTHER

collaborator

NYU Langone Health

OTHER

collaborator

Northwestern University

OTHER

collaborator

University of California, Los Angeles

OTHER

collaborator

University of California, San Diego

OTHER

collaborator

University of California, San Francisco

OTHER

collaborator

University of Miami

OTHER

collaborator

University of North Carolina, Chapel Hill

OTHER

collaborator

University of South Florida

OTHER

lead

Johns Hopkins Bloomberg School of Public Health

OTHER

NCT00000142 - Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT) | Biotech Hunter | Biotech Hunter